Skip to content

Clinical study for ''three steps'' external treatment of adult eczema

Clinical study for ''three steps'' external treatment of adult eczema

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2000003842
Enrollment
Unknown
Registered
2020-08-29
Start date
2020-10-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

adult eczema

Interventions

Sponsors

Shanghai Hospital of traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. those who meet the diagnostic criteria of Western medicine; 2. those who meet the diagnostic criteria of traditional Chinese medicine; 3. Aged 18-75 years old, both male and female; 4. informed consent, signed informed consent, and volunteered.

Exclusion criteria

Exclusion criteria: 1. those who do not meet the diagnostic criteria and inclusion criteria; 2. patients with severe liver and kidney dysfunction, severe cardiovascular and cerebrovascular diseases (such as pacemaker wearers, postoperative recovery period of heart disease, history of stroke, etc.), mental disease, malignant tumor, syringomyelia history, long-term systematic use of corticosteroids (including oral or intravenous drip) and endocrine system diseases; 3. accompanied with circulatory disorders (such as arterial embolism, Raynaud's disease, etc.), various hemorrhagic diseases and high fever; 4. patients with late acute inflammation, chronic inflammation or deep suppurative lesions, severe local skin damage, or patients with severe infection or skin lesion area greater than 10% of body surface area; 5. patients with systemic lupus erythematosus, cold allergy, limb replantation, allergic constitution or allergy to known drug ingredients; 6. pregnant or lactating women; 7. those who do not meet the inclusion criteria, fail to use drugs according to the regulations, cannot judge the curative effect, or the incomplete information affects the efficacy or safety judgment; 8. according to the researcher's judgment, there are other medical histories that reduce the possibility of enrollment or complicate the enrollment, such as frequent changes in the working environment, which may easily lead to loss of follow-up; 9. subjects who are participating in clinical studies of other drugs.

Design outcomes

Primary

MeasureTime frame
Lesion area;Lesion morphology;itch;

Secondary

MeasureTime frame
IL-18;IL-1ß;health-related quality of life;

Countries

China

Contacts

Public ContactLI Shujuan

Shanghai Hospital of traditional Chinese Medicine

LSJMMO@163.com+86 18321868601

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026